Pages that link to "Q69897087"
Jump to navigation
Jump to search
The following pages link to Jules Dienstag (Q69897087):
Displaying 50 items.
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon (Q27487518) (← links)
- Advancing patient care: integrating new data. (Q31031231) (← links)
- The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study (Q31839494) (← links)
- Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. (Q33378482) (← links)
- Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. (Q33618516) (← links)
- Processes to manage analyses and publications in a phase III multicenter randomized clinical trial (Q33694159) (← links)
- Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. (Q34072683) (← links)
- Outcome of sustained virological responders with histologically advanced chronic hepatitis C. (Q34101701) (← links)
- Comparison of serological tests for antibody to hepatitis A antigen, using coded specimens from individuals infected with the MS-1 strain of hepatitis A virus (Q34134574) (← links)
- Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. (Q34167963) (← links)
- Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial (Q34194979) (← links)
- Hepatitis B as an immune complex disease. (Q34246965) (← links)
- Purification of hepatitis A antigen from feces and detection of antigen and antibody by immune adherence hemagglutination (Q34390761) (← links)
- Quantitation of antibody to hepatitis A antigen by immune electron microscopy (Q34393440) (← links)
- Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C (Q34671935) (← links)
- Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. (Q34778315) (← links)
- The role of liver biopsy in chronic hepatitis C. (Q34984093) (← links)
- A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma (Q35085830) (← links)
- Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. (Q35091015) (← links)
- The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. (Q35124395) (← links)
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. (Q35131882) (← links)
- In Vitro Studies of Tobramycin, an Aminoglycoside Antibiotic (Q35637994) (← links)
- YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C (Q35823055) (← links)
- Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis (Q36015711) (← links)
- The high-risk liver allograft recipient. Should allocation policy consider outcome? (Q36065644) (← links)
- The pathology of viral hepatitis types A and B in chimpanzees. A comparison (Q36078142) (← links)
- American Gastroenterological Association technical review on the management of hepatitis C. (Q36364156) (← links)
- Looking to the future: new agents for chronic hepatitis B. (Q36382639) (← links)
- Prevention and Therapy of Viral Hepatitis (Q36679236) (← links)
- Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. (Q36687349) (← links)
- Recent advances in the identification of hepatitis viruses (Q36812111) (← links)
- Oral antivirals for chronic hepatitis B. (Q36991475) (← links)
- Inhibition of lymphocyte cytotoxicity by serum from patients with alcoholic liver disease: partial characterization of serum inhibitors (Q36998765) (← links)
- Hepatitis viruses: characterization and diagnostic techniques (Q36999169) (← links)
- Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. (Q37000501) (← links)
- Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. (Q37086216) (← links)
- Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease (Q37112127) (← links)
- Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. (Q37174403) (← links)
- Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. (Q37270537) (← links)
- Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. (Q37440725) (← links)
- Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. (Q37520019) (← links)
- Hepatitis A Virus Infection: New Insights from Seroepidemiologic Studies (Q37752704) (← links)
- The pathobiology of hepatitis A virus (Q38060279) (← links)
- Hepatitis A virus: identification, characterization, and epidemiologic investigations (Q38066262) (← links)
- Sexual and perinatal transmission of hepatitis C. (Q38556135) (← links)
- Distribution of Antibody to Hepatitis A Antigen in Urban Adult Populations (Q39205251) (← links)
- Antibody to hepatitis A antigen in children (Q39217731) (← links)
- Letter: Immune electron microscopy and hepatitis A (Q39312839) (← links)
- Faecal shedding of hepatitis-A antigen (Q39324210) (← links)
- Hepatitis A virus: virologic, clinical, and epidemiologic studies. (Q39341935) (← links)